ArticlePloS one2011
Newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Smart Cells Against Cancer: Advances in Cell-Based Drug Delivery and Diagnostics.Pharmaceutics · 2025Review
- Development of Cell-Derived Plasma Membrane Vesicles as a Nanoparticle Encapsulation and Delivery System.Cellular and molecular bioengineering · 2025Article
- Recent Progress in Nano-TCM Active Ingredient Co-Delivery Systems for Inflammation-Mediated Diseases.International journal of nanomedicine · 2025Review
- Red Blood Cell Inspired Strategies for Drug Delivery: Emerging Concepts and New Advances.Pharmaceutical research · 2022Review
- Erythro-Magneto-HA-Virosome: A Bio-Inspired Drug Delivery System for Active Targeting of Drugs in the Lungs.International journal of molecular sciences · 2022Article
- Silencing Survivin: a Key Therapeutic Strategy for Cardiac Hypertrophy.Journal of cardiovascular translational research · 2022Article
- Epigenetics in cancer therapy and nanomedicine.Clinical epigenetics · 2019Review
- Article
- Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization.Pharmaceutical research · 2014Article
- Preclinical evaluation of recombinant human IFNα2b-containing magnetoliposomes for treating hepatocellular carcinoma.International journal of nanomedicine · 2014Article
- Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo.Advanced healthcare materials · 2014Article
- Article
- Engineering antiphagocytic biomimetic drug carriers.Therapeutic delivery · 2013Review
- Physical principles for scalable neural recording.Frontiers in computational neuroscience · 2013Article
- Force dependent internalization of magnetic nanoparticles results in highly loaded endothelial cells for use as potential therapy delivery vectors.Pharmaceutical research · 2012Article
- Microfluidic synthesis of microfibers for magnetic-responsive controlled drug release and cell culture.PloS one · 2012Article
- New approaches to treat cancer - what they can and cannot do.Biotechnology healthcare · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.